{
    "clinical_study": {
        "@rank": "60391", 
        "arm_group": {
            "arm_group_label": "Diagnosis (intravital microscopy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies intravital microscopy for identifying tumor vessels in\n      patients with stage IA-IV melanoma that is being removed by surgery. New imaging procedures,\n      such intravital microscopy, may determine the extent of melanoma."
        }, 
        "brief_title": "Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery", 
        "condition": [
            "Recurrent Melanoma", 
            "Stage IA Melanoma", 
            "Stage IB Melanoma", 
            "Stage IIA Melanoma", 
            "Stage IIB Melanoma", 
            "Stage IIC Melanoma", 
            "Stage IIIA Melanoma", 
            "Stage IIIB Melanoma", 
            "Stage IIIC Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the feasibility of performing intravital microscopy on accessible human\n      melanoma tumors during their standard course of treatment (i.e., wide local excision). (Part\n      I)\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the blood flow velocity of the tumor vessels and tissue penetration of\n      fluorescein (fluorescein sodium) as a marker of tumor vessel permeability. (Part II)\n\n      OUTLINE:\n\n      Patients receive fluorescein sodium intravenously (IV) followed by intravital microscopic\n      observation over 10-15 minutes during excision of the melanoma.\n\n      After completion of study treatment, patients are followed up periodically for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 2\n\n          -  Have measurable disease in their skin by direct visualization (visible lesion\n             typically > 0.5 cm in maximal diameter); to perform a microscopic observation, the\n             lesion will have to be visible by the naked eye, lined-up visually, and be able to\n             interface with the microscope objective; a melanoma lesion that is smaller than 0.5\n             cm in diameter would present several obstacles to obtaining a reliable microscopic\n             observation in the operating room; therefore, a visible lesion, at a minimum of 0.5\n             cm in diameter, is proposed for this study\n\n          -  Melanoma tumor that requires a wide local excision in the operating room; this may\n             include any stage of melanoma from Stage IA to Stage IV that requires a wide excision\n             in the operating room\n\n          -  Subject or legal representative must understand the investigational nature of this\n             study and sign an Independent Ethics Committee/Institutional Review Board approved\n             written informed consent form prior to receiving any study related procedure\n\n          -  To determine any sensitivity to fluorescein, subject must have a skin prick test\n             preoperatively (at the time of the preoperative visit and after signed informed\n             consent for entry into this clinical trial is given); a negative skin prick test to\n             fluorescein is an inclusion criteria\n\n        Exclusion Criteria:\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Melanoma deposit is deemed inaccessible to microscopic observation during the\n             operative procedure (i.e., lesion is less than 0.5 cm or is not clearly visible to\n             the naked eye)\n\n          -  Renal dysfunction as defined as a glomerular filtration rate (GFR) < 70\n\n          -  Any known allergy or prior reaction to fluorescein; also, a positive skin prick test\n             to fluorescein is considered an exclusion criteria and the patient would not be\n             eligible for entry into this study\n\n          -  Pregnant or nursing female subjects\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Any condition which in the Investigator's opinion deems the subject an unsuitable\n             candidate to undergo observational study (may also include preoperative testing\n             results including electrocardiogram [EKG], chest x-ray, or pulmonary function tests\n             that preclude a wide excision in the operating room)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886235", 
            "org_study_id": "I 231512", 
            "secondary_id": [
                "NCI-2013-01052", 
                "I 231512", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnosis (intravital microscopy)", 
                "description": "Given IV", 
                "intervention_name": "fluorescein sodium injection", 
                "intervention_type": "Drug", 
                "other_name": "Fluorescite"
            }, 
            {
                "arm_group_label": "Diagnosis (intravital microscopy)", 
                "description": "Undergo intravital microscopy", 
                "intervention_name": "diagnostic microscopy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnosis (intravital microscopy)", 
                "description": "Undergo surgery", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnosis (intravital microscopy)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@RoswellPark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Joseph J. Skitzki", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Feasibility of Performing Intravital Microscopy in Melanoma Patients", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Joseph Skitzki", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A successful intravital microscopic observation will include the ability to identify tumor vessels, measure tumor vessel diameters, determine vessel density per 10 x field and visualize fluorescein within the tumor vessels.", 
            "measure": "Feasibility of performing intravital microscopy on accessible human melanoma tumors during standard local excision", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886235"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Described using upper one-sided 95% Clopper Pearson confidence limits.", 
                "measure": "Adverse event rate", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Described using upper one-sided 95% Clopper Pearson confidence limits.", 
                "measure": "Complication rate", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Sample tumor characteristics obtained from the intervention will be characterized using descriptive statistics (mean, medians) and 95% confidence intervals.", 
                "measure": "Tumor vasculature", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months"
            }, 
            {
                "description": "Sample tumor characteristics obtained from the intervention will be characterized using descriptive statistics (mean, medians) and 95% confidence intervals.", 
                "measure": "Blood flow rates", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months"
            }, 
            {
                "description": "Associations between tumor characteristics and treatment response will be assessed using Logistic Regression methods.", 
                "measure": "Treatment response", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes. Data will be correlated with findings from the one-time, initial intravital microscopy observation for the defined 5-year period of data collection.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes. Data will be correlated with findings from the one-time, initial intravital microscopy observation for the defined 5-year period of data collection.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}